Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;9(2):84-89.
doi: 10.20407/fmj.2022-003. Epub 2022 Jul 22.

Dry loop-mediated isothermal amplification assay for detection of SARS-CoV-2 from clinical specimens

Affiliations

Dry loop-mediated isothermal amplification assay for detection of SARS-CoV-2 from clinical specimens

Yuki Higashimoto et al. Fujita Med J. 2023 May.

Abstract

Objectives: To establish a point-of-care test for coronavirus disease 2019 (COVID-19), we developed a dry loop-mediated isothermal amplification (LAMP) method to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA.

Methods: We carried out reverse transcription (RT)-LAMP using the Loopamp SARS-CoV-2 Detection kit (Eiken Chemical, Tokyo, Japan). The entire mixture, except for the primers, is dried and immobilized inside the tube lid.

Results: To determine the specificity of the kit, 22 viruses associated with respiratory infections, including SARS-CoV-2, were tested. The sensitivity of this assay, determined by either a real-time turbidity assay or colorimetric change of the reaction mixture, as evaluated by the naked eye or under illumination with ultraviolet light, was 10 copies/reaction. No LAMP product was detected in reactions performed with RNA from any pathogens other than SARS-CoV-2. After completing an initial validation analysis, we analyzed 24 nasopharyngeal swab specimens collected from patients suspected to have COVID-19. Of the 24 samples, 19 (79.2%) were determined by real-time RT-PCR analysis as being positive for SARS-CoV-2 RNA. Using the Loopamp SARS-CoV-2 Detection kit, we detected SARS-CoV-2 RNA in 15 (62.5%) of the 24 samples. Thus, the sensitivity, specificity, positive predictive value, and negative predictive values of the Loopamp 2019-CoV-2 detection reagent kit were 78.9%, 100%, 100%, and 55.6%, respectively.

Conclusions: The dry LAMP method for detecting SARS-CoV-2 RNA is fast and easy to use, and its reagents can be stored at 4°C, solving the cold chain problem; thus, it represents a promising tool for COVID-19 diagnosis in developing countries.

Keywords: COVID-19; LAMP; Real-time RT-PCR; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflict of interest with regard to this work.

Figures

Figure 1
Figure 1
Sensitivity of the SARS-CoV-2 dry LAMP assay as determined using serially diluted in vitro-transcribed RNA. (a) Naked-eye detection at the end of the assay (35 min). Green indicates a positive reaction, and orange indicates a negative reaction. (b) Ultraviolet light detection at the end of the assay (35 min). Light gray indicates a positive reaction, and dark gray indicates a negative reaction. (C) Real-time turbidity assay.

Similar articles

Cited by

References

    1. Wu F, Zhao S, Yu B, et al. . A new coronavirus associated with human respiratory disease in China. Nature 2020; 579: 265–269. - PMC - PubMed
    1. Zhou P, Yang XL, Wang XG, et al. . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579: 270–273. - PMC - PubMed
    1. Bimonte S, Crispo A, Amore A, Celentano E, Cuomo A, Cascella M. Potential antiviral drugs for SARS-Cov-2 treatment: preclinical findings and ongoing clinical research. In Vivo 2020; 34: 1597–1602. - PMC - PubMed
    1. Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med 2022; 386: 1397–1408. - PMC - PubMed
    1. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. . Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med 2022; 386: 509–520. - PMC - PubMed